Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
Hyperuricemia is an increase of uric acid (UA) concentration in blood serum >420 pmol/L in men or >360 pmol/L in women and is considered to be a common biochemical abnormality. This condition shows that the extracellular fluid is oversaturated with urates, which concentration exceeds t...
Saved in:
| Main Authors: | Taras S. Panevin, Olga V. Zhelyabina, Maxim S. Eliseev, Marina V. Shestakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2020-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12412 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study
by: O. V. Zhelyabina, et al.
Published: (2022-02-01) -
Urate-lowering therapy for heart failure
by: O. V. Zhelyabina, et al.
Published: (2019-09-01) -
Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01) -
Is Urate-lowering therapy a prevention of first gout episode?
by: Michał Szczepański, et al.
Published: (2025-07-01) -
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)